[1]何 钰,王建波,王 武.内动脉粥样硬化性狭窄支架植入术后再狭窄机制及治疗新进展[J].介入放射学杂志,2021,30(11):1184-1189.
　HE Yu,WANG Jianbo,WANG Wu.The mechanism of restenosis in patients with intracranial atherosclerotic stenosis after receiving stent implantation and the latest progress in its clinical treatment[J].journal interventional radiology,2021,30(11):1184-1189.
点击复制

内动脉粥样硬化性狭窄支架植入术后再狭窄机制及治疗新进展()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年11
页码:
1184-1189
栏目:
综述
出版日期:
2021-11-25

文章信息/Info

Title:
The mechanism of restenosis in patients with intracranial atherosclerotic stenosis after receiving stent implantation and the latest progress in its clinical treatment
作者:
何 钰;  王建波;  王 武
Author(s):
HE Yu;  WANG Jianbo;  WANG Wu
Department of Interventional Radiology， Shanghai Municipal Sixth People’s Hospital， Shanghai 200233， China
关键词:
【关键词】 颅脑动脉;  动脉粥样硬化;  支架;  再狭窄;  血管内治疗
文献标志码:
A
摘要:
【摘要】 颅内动脉粥样硬化性狭窄（ICAS）是缺血性脑卒中的主要病因。随着脑血管介入治疗理念和材料不断发展，脑血管介入支架已成为ICAS首选治疗策略。但支架植入后支架内再狭窄（ISR）问题异常突出，其原因和机制较为复杂，涉及内皮细胞和平滑肌细胞过度增殖及再次动脉粥样硬化形成。目前ICAS介入治疗的重点和难点仍然是术后ISR预防和治疗。该文主要综述ICAS支架植入术后ISR机制和血管内再介入治疗研究进展及展望，旨在为临床治疗决策提供新思考和方向。

参考文献/References:

［1］ Qureshi AI， Caplan LR. Intracranial atherosclerosis［J］. Lancet， 2014， 383： 984- 998.
［2］ Wang Y， Zhao X， Liu L，et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China： the Chinese Intracranial Atherosclerosis（CICAS） Study［J］. Stroke， 2014， 45： 663-669.
［3］ Wang Y， Meng R， Liu G，et al. Intracranial atherosclerotic disease［J］. Neurobiol Dis， 2019， 124： 118-132.
［4］ Alfonso F， Perez-Vizcayno MJ， Cardenas A，et al. A prospective randomized trial of drug- eluting balloons versus everolimus-eluting stents in patients with in- stent restenosis of drug- eluting stents： the RIBS Ⅳ randomized clinical trial［J］. J Am Coll Cardiol， 2015， 66： 23-33.
［5］ Sun X， Ma N， Wang B，et al. The long term results of vertebral artery ostium stenting in a single center［J］. J Neurointerv Surg， 2015， 7： 888-891.
［6］ Lopez- Cancio E， Galan A， Dorado L，et al. Biological signatures of asymptomatic extra- and intracranial atherosclerosis： the Barcelona- AsIA（Asymptomatic Intracranial Atherosclerosis） study［J］. Stroke， 2012， 43： 2712-2719.
［7］ Dang M， Song Y， Li Q，et al. Genetic variation of the kalirin gene is associated with ICAS in the Chinese population［J］. J Mol Neurosci， 2018， 66： 157-162.
［8］ Wu JH， Fanaroff AC， Sharma KC，et al. Kalirin promotes neointimal hyperplasia by activating Rac in smooth muscle cells［J］. Arterioscler Thromb Vasc Biol， 2013， 33： 702-708.
［9］ Stary HC， Chandler AB， Glagov S，et al. A definition of initial， fatty streak， and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arte-riosclerosis，American Heart Association［J］. Circulation， 1994， 89： 2462-2478.
［10］ Papanagiotou P， Roth C， Walter S，et al. Carotid artery stenting in acute stroke［J］. J Am Coll Cardiol， 2011， 58： 2363-2369.
［11］ Cohen DJ， Stolker JM， Wang K，et al. Health-related quality of life after carotid stenting versus carotid endarterectomy： results from CREST（Carotid Revascularization Endarterectomy Versus Stenting Trial）［J］. J Am Coll Cardiol， 2011， 58： 1557-1565.
［12］ Brott TG， Hobson RW 2nd， Howard G，et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis［J］. N Engl J Med， 2010， 363： 11-23.
［13］ Derdeyn CP， Chimowitz MI， Lynn MJ，et al. Aggressive medical treatment with or without stenting in high- risk patients with intracranial artery stenosis（SAMMPRIS）： the final results of a randomised trial［J］. Lancet， 2014， 383： 333-341.
［14］ Shlofmitz E， Iantorno M， Waksman R. Restenosis of drug-eluting stents： a new classification system based on disease mechanism to guide treatment and state-of-the-art review［J］. Circ Cardiovasc Interv， 2019， 12： e007023.
［15］ Jensen LO， Vikman S， Antonsen L，et al. Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in- stent restenosis after drug- eluting or bare- metal stent implantation. The Nordic Intravascular Ultrasound Study（NIVUS）［J］. Cardiovasc Revasc Med， 2017， 18： 577-582.
［16］ Arbustini E， Favalli V， Narula J. Functionally incomplete re-endothelialization of stents and neoatherosclerosis［J］. JACC Cardiovasc Interv， 2017， 10： 2388-2391.
［17］ Zhao LP， Xu WT， Wang L，et al. Influence of insulin resistance on in- stent restenosis in patients undergoing coronary drug- eluting stent implantation after long- term angiographic follow- up［J］. Coron Artery Dis， 2015， 26： 5-10.
［18］ Zhou Z， Yin Q， Xu G，et al. Influence of vessel size and tortuosity on in- stent restenosis after stent implantation in the vertebral artery ostium［J］. Cardiovasc Intervent Radiol， 2011， 34： 481- 487.
［19］ Muller MD， Gregson J， McCabe DJH，et al. Stent design， restenosis and recurrent stroke after carotid artery stenting in the international carotid stenting study［J］. Stroke， 2019， 50： 3013-3020.
［20］ 刘晓哲， 王 兵， 刘俊超，等. 药物涂层球囊在股腘动脉支架内再狭窄治疗中的应用［J］. 介入放射学杂志， 2018， 27： 410-414.
［21］ Strobel HA， Qendro EI， Alsberg E，et al. Targeted delivery of bioactive molecules for vascular intervention and tissue engineering［J］. Front Pharmacol， 2018， 9： 1329.
［22］ Chu J， Chen L， Mo Z，et al. An atorvastatin calcium and poly（L-lactide- co- caprolactone） core- shell nanofiber- covered stent to treat aneurysms and promote reendothelialization［J］. Acta Biomater， 2020， 111： 102-117.
［23］ Zhang Y， Wang J， Xiao J，et al. An electrospun fiber-covered stent with programmable dual drug release for endothelialization acceleration and lumen stenosis prevention［J］. Acta Biomater， 2019， 94： 295-305.
［24］ Power S， Slattery MM， Lee MJ. Nanotechnology and its relationship to interventional radiology. Part Ⅱ： drug delivery， thermotherapy， and vascular intervention［J］. Cardiovasc Intervent Radiol， 2011， 34： 676-690.
［25］ Liu P， Liu Y， Li P，et al. Rosuvastatin- and heparin- loaded poly（l- lactide- co- caprolactone） nanofiber aneurysm stent promotes endothelialization via vascular endothelial growth factor type A modulation［J］. ACS Appl Mater Interfaces， 2018， 10： 41012- 41018.
［26］ Luderer F， Lobler M， Rohm HW，et al. Biodegradable sirolimus-loaded poly（lactide） nanoparticles as drug delivery system for the prevention of in- stent restenosis in coronary stent application［J］. J Biomater Appl， 2011， 25： 851-875.
［27］ Ali RM， Abdul Kader MASK， Wan Ahmad WA， et al. Treatment of coronary drug- eluting stent restenosis by a sirolimus- or paclitaxel- coated balloon［J］. JACC Cardiovasc Interv， 2019， 12： 558-566.
［28］ Yamagami H， Sakai N， Matsumaru Y，et al. Periprocedural cilostazol treatment and restenosis after carotid artery stenting： the Retrospective Study of In- Stent Restenosis after Carotid Artery Stenting（ReSISteR- CAS）［J］. J Stroke Cerebrovasc Dis， 2012， 21： 193-199.
［29］ Lammer J， Zeller T， Hausegger KA，et al. Heparin- bonded covered stents versus bare- metal stents for complex femoropopliteal artery lesions： the randomized VIASTAR trial［Viabahn endoprosthesis with PROPATEN bioactive surface（VIA） versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease］［J］. J Am Coll Cardiol， 2013， 62： 1320-1327.
［30］ Zhou L， Liu D， Li Y，et al. Argatroban for preventing occlusion and restenosis after extracranial artery stenting［J］. Eur Neurol， 2014， 71： 319-325.
［31］ Shi R， Zhang R， Yang F，et al . Tissue kallikrein prevents restenosis after stenting of severe atherosclerotic stenosis of the middle cerebral artery：a randomized controlled trial［J］. Medicine（Baltimore）， 2016， 95： e2809.
［32］ Kuang H， Wang Y， Hu J，et al. A method for preparation of an internal layer of artificial vascular graft co- modified with salvianolic acid B and heparin［J］. ACS Appl Mater Interfaces， 2018， 10： 19365-19372.
［33］ Zhang F， Zhang Q， Li X，et al. Mussel-inspired dopamine- CuⅡcoatings for sustained in situ generation of nitric oxide for prevention of stent thrombosis and restenosis［J］. Biomaterials， 2019， 194： 117-129.
［34］ Park J， Seo H， Hwang HW，et al. Interface engineering of fully metallic stents enabling controllable H2O2 generation for antires-tenosis［J］. Langmuir， 2019， 35： 3634-3642.
［35］ Gao J， Jiang L， Liang Q，et al. The grafts modified by hepari-nization and catalytic nitric oxide generation used for vascular implantation in rats［J］. Regen Biomater， 2018， 5： 105-114.
［36］ Huang C， Zhou M， Zheng X. RhoA inhibitor- eluting stent attenuates restenosis by inhibiting YAP signaling［J］. J Vasc Surg， 2019， 69： 1581-1589.e1.
［37］ 郑 辉， 郭富强. Rho/Rho激酶信号通路与支架内再狭窄的研究［J］. 介入放射学杂志， 2012， 21： 172-175
［38］ Wen M， Zhi D， Wang L，et al. Local delivery of dual microRNAs in trilayered electrospun grafts for vascular regeneration［J］. ACS Appl Mater Interfaces， 2020， 12： 6863-6875.
［39］ Nestelberger T， Kaiser C， Jeger R. Drug- coated balloons in cardiovascular disease： benefits， challenges， and clinical appli-cations［J］. Expert Opin Drug Deliv， 2020， 17： 201-211.
［40］ 曾书燚， 王正东， 陈 坚，等. 药物洗脱球囊与药物洗脱支架治疗支架内再狭窄疗效比较［J］. 介入放射学杂志， 2017， 26： 839-842.
［41］ He C， Wang S， Zhou X，et al. A Review on the comparison of different treatments for carotid in-stent restenosis［J］. Can J Neurol Sci， 2019， 46： 666- 681.
［42］ 张成超， 谷涌泉， 齐立行，等. 药物涂层球囊扩张成形术治疗颈动脉支架内再狭窄2例［J］. 介入放射学杂志， 2019， 28： 159-161.
［43］ den Dekker WK， Houtgraaf JH， Onuma Y，et al. Final results of the HEALING IIB trial to evaluate a bio- engineered CD34 antibody coated stent（GenousStent） designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients［J］. Atherosclerosis， 2011， 219： 245-252.
［44］ Saleh YE， Gepreel MA， Allam NK. Functional nanoarchitectures for enhanced drug eluting stents［J］. Sci Rep， 2017， 7： 40291.
［45］ Adeel MY， Sharif F. Advances in stent-mediated gene delivery［J］. Expert Opin Drug Deliv， 2016， 13： 465- 468.
［46］ Cornelissen A， Vogt FJ. The effects of stenting on coronary endothelium from a molecular biological view： time for impro- vement?［J］. J Cell Mol Med， 2019， 23： 39- 46.
［47］ Goel SA， Guo LW， Liu B，et al. Mechanisms of post-intervention arterial remodelling［J］. Cardiovasc Res， 2012， 96： 363-371.
［48］ Inoue T， Croce K， Morooka T，et al. Vascular inflammation and repair： implications for re-endothelialization， restenosis， and stent thrombosis［J］. JACC Cardiovasc Interv， 2011， 4： 1057-1066.
［49］ Chen Y， Gao L， Qin Q，et al. Comparison of 2 different drug- coated balloons in in- stent restenosis： the RESTORE ISR China randomized trial［J］. JACC Cardiovasc Interv， 2018， 11： 2368-2377.

相似文献/References:

[1]徐迎佳,方唯一,杨向军.冠脉钙化小结血管内超声影像识别、发生率和分布特征[J].介入放射学杂志,2011,(08):606.
　XU Ying-jia,FANG Wei-yi,YANG Xiang-jun..The occurrence and distribution features of calcified nodules in coronary arteries determined by intravascular ultrasonography[J].journal interventional radiology,2011,(11):606.
[2]黄志志.椎动脉硬化性闭塞介入再通一例[J].介入放射学杂志,2013,(04):345.
　HUANG Zhi- zhi..Re- canalization of vertebral arteriosclerotic occlusion with stent implantation： report of one case[J].journal interventional radiology,2013,(11):345.
[3]梅百强,杨希立,许兆延,等.H型高血压患者斑块特征与同型半胱氨酸相关性研究 [J].介入放射学杂志,2016,(01):70.
　MEI Bai- qiang,YANG Xi- li,XU Zhao- yan,et al.Study on the relationship between plaque imaging characteristics and homocysteine in patients with H- type hypertension [J].journal interventional radiology,2016,(11):70.
[4]岑锦明,杨希立,许兆延,等.iMapTM血管内超声检测冠状动脉粥样斑块坏死核心与心血管疾病危险因素、Lp- PLA2相关性[J].介入放射学杂志,2018,27(12):1134.
　CEN Jinming,YANG Xili,XU Zhaoyan,et al.The relationship of coronary atherosclerotic plaque necrosis core measured by iMapTM intravascular ultrasound to cardiovascular disease risk factors and LP- PLA2[J].journal interventional radiology,2018,27(11):1134.
[5]钱锦铧,迟庆杰,丁文彬,等.无症状性颈动脉狭窄患者颈动脉支架植入治疗的研究进展[J].介入放射学杂志,2025,34(08):905.[doi:10.3969/j.issn.1008-794X.2025.08.019 ]
　QIAN Jinhua,CHI Qingjie,DING Wenbin,et al.Research progress in carotid artery stenting for patients with asymptomatic carotid atherosclerotic stenosis[J].journal interventional radiology,2025,34(11):905.[doi:10.3969/j.issn.1008-794X.2025.08.019 ]
[6]杨 靖,葛均波.泛血管理念在介入诊疗中的展望[J].介入放射学杂志,2026,(02):119.[doi:10.3969/j.issn.1008-794X.2026.02.001 ]
　YANG Jing,GE Junbo..The application prospects of pan-vascular concept in interventional diagnosis and treatment[J].journal interventional radiology,2026,(11):119.[doi:10.3969/j.issn.1008-794X.2026.02.001 ]

备注/Memo

备注/Memo:
（收稿日期：2020-06-18）
（本文编辑：边 佶）
更新日期/Last Update: 2021-11-22